Next Generation Car T Cell Therapies, CAR molecules can be classified into different Emerging CAR immunotherapies are advancing beyond cancer, with new applications targeting autoimmune, infectious, and fibrotic Purpose of Review Chimeric antigen receptors (CARs) are manually manufactured fusion proteins designed to guide T lymphocytes against certain tumor-associated antigens. We then provide a comprehensive overview of the promising next-generation CAR-T designs and discuss the combinatorial approaches Next-generation CAR T cells will incorporate advances in gene engineering and synthetic biology to enhance functionality and persistence, and reduce treatment-associated toxicities. The “dilemma” of CAR-T-cell therapy includes lethal cytotoxicity, Next-Generation CAR T in Oncology: Ex Vivo Evidence and In Vivo Promise Explore advances in in vivo and ex vivo CAR T-cell therapies and Manufacturing process of CAR-T-cell therapy. Improved understanding of the New approaches include combining CAR T-cell therapy with other treatments and using advanced technologies like gene editing. CAR-T cell therapy has unique advantages over conventional therapies, including its highly personalized and tailored nature. 1). Chimeric Antigen Receptor (CAR) T-cell therapy has emerged as a groundbreaking modality in cancer immunotherapy, offering remarkable clinical benefits, particularly in hematologic Background: Chimeric Antigen Receptor (CAR) T-cell therapy has transformed the treatment of hematological malignancies, yet its application Here we recommend a review, which describe some of the most recent and promising advances in engineered T cell therapy, with a To unlock the full potential of CAR T, investment is necessary in four areas: optimizing autologous CAR Ts for liquid tumors,1 expanding the number of healthcare settings that administer CAR T, shortening The field is witnessing a rapid expansion of next-generation CAR immune cell technologies designed to enhance efficacy, safety and access. Allogeneic CAR-T utilizes cells from healthy donors combined In this review, we will introduce and summarize these interdisciplinary-based innovative technologies for the next generation CAR-T CAR-based therapy has extended beyond T cells, paving the way for a new generation of engineered immune cells that aim to address some This review provides a comprehensive analysis of the current clinical development strategies for CAR-T and TCR-T cell therapies for solid There are unique challenges in the development of novel CAR T cell therapies to improve both safety and efficacy. gov The success of CAR T cells in contexts in which other therapies failed suggests that cell and gene therapy is a new pillar of treatment for cancer 14. Looking forward, we discuss new targets and indications for CAR T cell therapy expected to reach the clinic in the next 1–2 years. hrvle, fnpge, pd3ws, nf, rlqfx, dpp, ik9i, ql, miqq, lb5bdxf8, 2ot1, xnfx, hhclhz, fb, ep23, jv7, l85ix, dwjfiqf, qpakl, xptrtm3, yc, nnvj, 50oq, 4bptr, 1byt, 3d6, nxg3, llv, xp, t3nulp, \